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Pulmonary lymphangioleiomyomatosis (LAM) is characterized by the proliferation of abnormal
smooth muscle cells (LAM cells) and destruction of alveolar structure. Immunohistochemical
studies suggest that excess matrix metalloproteinases (MMPs) synthesized by LAM cells func-
tion in the proteolytic mechanisms of this disease. We postulated MMP levels in the blood
are elevated in LAM patients. Serum samples were collected from 36 LAM patients and 25
controls, and gelatinolytic activities were semi-quantified by gelatin zymography. The reli-
ability of serum data for MMP-9 was confirmed by the measurement of MMP-9 concentration
in plasma by enzyme-linked immunosorbent assay as well as by gelatin zymography. Serum
levels of MMP-9 (0.7  0.1 AU), but not MMP-2, were significantly elevated in LAM patients
compared with controls (0.1 0 AU). Plasma and serum levels of MMP-9 significantly corre-
lated. These results suggest the involvement of MMP-9 in LAM.
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Lymphangioleiomyomatosis (LAM) is a rare disease charac-
terized by recurrent spontaneous pneumothorax, chylo-
thorax, chylous ascites and angiomyolipomas that primarily
affects women of childbearing age.1 The primary patho-
logical findings in LAM include the abnormal proliferation of
smooth muscle-like cells (LAM cells) in the pulmonary
interstitium and along the axial lymphatics in the thorax
and abdomen.2.
MMP-9 in blood with lymphangioleiomyomatosis 125Matrix metalloproteinases (MMPs) comprise a family of
at least 25 extracellular matrix-degrading, zinc-dependent
enzymes. Although MMPs play an important physiological
role in tissue remodeling and repair, their overexpression
is linked to various chronic pulmonary diseases.3 The
gelatinases, MMP-2 and MMP-9, can degrade native type IV
collagen, denatured type I collagen (gelatin) and elastic
fiber.4,5 Immunohistochemical studies have found that
MMP-2 and MMP-9 are predominantly expressed in LAM
cells, implying that they are involved in the destructive
cystic formation associated with pulmonary LAM.6,7
Until recently, LAM cells have been considered histo-
logically benign not only in sporadic LAM, but also in
tuberous sclerosis complex (TSC)-related LAM. However,
compelling evidence such as the recurrence of LAM after
lung transplantation and the presence of LAM cells with the
same mutation in the lung, lymph nodes and kidney
suggests that LAM cells can migrate and metastasize.8e11
Crooks et al. also demonstrated that disseminated LAM
cells carry a TSC2 loss of heterozygosity (LOH) in the body
fluids of patients with LAM.12 Kumasaka et al. also recently
reported that lymphangiogenesis is prominent in regions of
LAM and that LAM cells are shed into the blood circulation
via lymphatic circulation.13,14
Considering that LAM cells which over-produce MMPs are
not restricted to the lungs, levels of circulating MMPs might
also be augmented, presumably as a result of their release
from affected organs and/or from circulating LAM cells. We
therefore postulated that MMP-9 and MMP-2 levels are
elevated in the blood circulation of patients with pulmo-
nary LAM.
The present study initially validated the usefulness of
measuring serum MMP levels by gelatin zymography, that is,
the pre-analytical condition of serum, the potential effect
of the menstrual cycle, and a correlation between serum
and plasma samples. We then quantified serum levels of
MMP-9 and MMP-2 by gelatin zymography in patients with
pulmonary LAM.
Material and methods
Participants
The study population consisted of 36 female patients with
LAM and age-matched 25 healthy females of childbearing
age (controls). Among the 36 LAM patients, 24 were from
Juntendo University and four from Kyushu University. We
diagnosed LAM based on standard histopathological findings
in lung biopsy tissues obtained from 24 patients using video-
assisted thoracoscopy. We diagnosed LAM in the others
based on a combination of multiple thin-walled cysts in the
lungs on computed tomography and clinical diagnostic
criteria,15e17 such as recurrent pneumothorax and/or chy-
lothorax, chylous ascites, abdominal lymphangioleiomyo-
mas and/or angiomyolipomas. We graded the severity of
cystic lung disease from HRCT as described.18 Briefly, the
extent of cystic involvement in each zone was graded as
follows: mild, cysts involving less than one-third of the
lungs; moderate, cysts involving one- to two-thirds of the
lungs; and severe, cysts involving more than two-thirds of
the lungs. Patients with infections or cancers wereexcluded from this study. Spirometry was performed
according to the standard method. Vital capacity, forced
expiratory volume in 1 s and diffusing capacity for carbon
monoxide were measured in all clinically stable patients
within 6 months of blood sampling (CHESTAC-55V; Chest
Co., Tokyo, Japan). The normal controls were volunteers
from among the medical staff and students recruited using
various public advertisements at Hokkaido University
School of Medicine. Written informed consent was obtained
from each patient and volunteer participating in the study,
and the Ethics Committees of Hokkaido, Juntendo and
Kyushu Universities approved the study.
Blood sampling
Venous blood samples were collected into Vacutainer
tubes containing clot activator and dipotassium EDTA for
serum and plasma preparations, respectively. The tubes
were centrifuged at 3000 rpm at 4 C for 10 min and stored
at 80 C.
Gelatin zymography
We assessed the gelatinolytic activities of blood by gelatin
zymography as described.19 In brief, samples were resolved
by electrophoresis on 8% (w/v) polyacrylamide gels con-
taining 1 mg/dl gelatin in the presence of sodium dodecyl
sulfate under non-reducing conditions. The gels were
washed in 2.5% Triton X-100 for 30 min, rinsed briefly, and
incubated at 37 C for 18 h in a buffer containing 50 mM
TriseHCl, pH 8.0, 5 mM CaCl2 and 1 mM ZnCl2. The gels
were stained with Coomassie blue R-250 and destained,
then enzyme activity was detected as unstained bands
against a blue background.
Semi-quantitative analysis of MMP-9 and MMP-2 by
gelatin zymography
To semi-quantify gelatinolytic activities, zymograms were
captured using a Scan Jet II cx/T (HewlettePackard, Palo
Alto, CA) and band intensity was calculated using NIH Image
software (version 1.54, ML). The relationship between
known amounts of serially diluted MMP-9 and MMP-2
(CC073; Chemicon) and the intensity of gelatinolytic bands
at 92 and 72 kDa was assessed within their respective linear
ranges, which were repeated for each assay (Fig. 1A and B).
Serum and plasma samples were diluted 40-fold. The
activities of MMPs in each sample were calculated by
dividing the optical intensity of bands at 92 or 72 kDa by the
value of the standard MMPs on each zymogram and are
described in arbitrary units (AU).
Enzyme-linked immunosorbent assays (ELISAs) of
plasma MMP-9
We purchased ELISA kits for MMP-9 from Amersham Phar-
macia Biotech (Little Chalfont, UK). Levels of MMP-9 in
plasma were measured as the recognition of latent forms or
of complexes with tissue inhibitor of metalloproteinase-1.
The detection limit of the assay was 0.6 ng/ml. All samples
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Figure 1 Evaluation of linear range between amounts of MMPs and integrated optical density (AU) on gelatin zymography and
comparison of serum samples with blood sampling time, menstrual cycle, and plasma samples. (A) Amounts of MMP-9 integrated
optical density (AU) (rZ 1.0). (B) Amounts of MMP-2 significantly correlated with integrated optical density (AU) (rZ 1.0). Gray
circle, standard sample loaded on each gel. (C) Levels of MMP-9 were elevated at 24 h after blood sampling. Up to 6 h between
blood sampling and centrifugation did not affect levels of MMP-9. Data are mean (SE) values for each group. *Difference from 0.5 h
(pZ 0.0015 for 24 h). (D) Menstrual phase also did not affect serum MMP-9 levels. (E) Serum MMP-9 was positively related to plasma
MMP-9 level determined by gelatin zymography (rZ 0.6, pZ 0.0017). (F) Serum levels of MMP-9 and plasma level of MMP-9
determined by ELISA were positively related (rZ 0.5, pZ 0.0187).
126 N. Odajima et al.were assayed in duplicate and values fell within the linear
portion of the standard curve.Statistical analysis
Results are expressed as means standard error of the
mean (SEM). Data were statistically analyzed using the
Bonferroni/Dunn test or Student’s paired t-test for pre-
analytical studies. Differences between two groups were
compared using Student’s unpaired t-test. Pearson’s
correlation coefficients or Spearman’s correlation coeffi-
cients were calculated to assess relationships between two
parameters (StatView J 5.0; SAS Institute Inc., Cary, NC). A
value of p< 0.05 was considered statistically significant.Results
Characteristics of the participants
Table 1 and Table E1 (Supplementary data) show the
clinical characteristics of all patients with LAM who
participated in the entire study. Airflow limitation was
frequent in the patients.
Pre-analytical conditions for MMP-9 measurements
in blood
To eliminate any artifactual effects on serum MMP-9 levels,
we first examined the effects of time between blood
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MMP-9 in blood with lymphangioleiomyomatosis 127sampling and centrifugation on the serum levels of MMP-9
or MMP-2. We collected the tubes of blood which were
centrifuged after 0.5, 1, 2, 6 or 24 h at room temperature
from four controls. The serum MMP-9 levels were 1.6 0.1
fold higher only when the blood remained at room
temperature for over 24 h after sampling compared with
0.5 h (pZ 0.0015; Fig. 1C). In contrast, the level of MMP-2
in serum did not change over time between sampling and
centrifugation (data not shown). We then examined
whether the menstrual cycle affects serum levels of MMP-9
or MMP-2. We collected three serum samples from each of
nine normal controls at the menstrual, proliferative, and
secretory phases of the menstrual cycle. Serum levels of
MMP-9 and MMP-2 remained constant throughout the
menstrual cycle (Fig. 1D and data not shown, respectively).
Correlation between serum and plasma MMP-9
levels
Meisser et al. have recently reported that plasma is pref-
erable to serum for measuring MMPs.20 We thus evaluated
whether levels of serum and plasma MMP-9 correlate in
using nine samples from the patients with LAM, and 14 from
normal controls. Gelatin zymography and ELISA results
showed that the serum and plasma levels of MMP-9 signifi-
cantly correlated (rZ 0.6, pZ 0.0029; Fig. 1E and rZ 0.5,Table 1 Clinical characteristics of LAM patients.
Number of participants
(female/male)
36 (36/0)
Age (y) 34 1
Smoker 8/36
Tuberous sclerosis (TS) 5/36
Angiomyolipoma 12/36
Abdominal lymphangioleiomyoma 4/36
Clinical features
Dyspnea 9/36
Pneumothorax 15/36
Chylothorax 3/36
Pathological diagnosis of LAM 24/36
HRCT findings (multiple cyst) 36/36
HRCT grades
Mild 12/36
Moderate 9/36
Severe 15/36
Pulmonary function
VC (% predicted) 94 3 (38e126)
FEV1 (ml) 1899 125 (510e3200)
FEV1 (% predicted) 71 5 (20e111)
FEV1/FVC (%) 68 3 (34e95)
DLCO (% predicted) 44 5 (14e112)
Hormonal manipulation
GnRH 16/36
Progesterone 2/36
Mean SEM (range), DLCO: diffusing capacity for carbon
monoxide, FEV1: forced expiratory volume in 1 s, FEV1/FVC:
forced expiratory volume in 1 s/forced vital capacity, GnRH:
gonadotropin-releasing hormone, HRCT: high-resolution
computed tomography scans, LAM: lymphangioleiomyomatosis,
VC: vital capacity.pZ 0.0187; Fig. 1F, respectively), suggesting that serum
data of MMPs are also reliable as plasma ones.
Serum levels of MMP-9 and MMP-2 in patients with
LAM and controls
Fig. 2A shows a representative zymogram of serum from
patients with LAM and from normal controls. Three distinct
gelatinolytic bands with molecular masses of 92, 130 and
220 kDa migrated, although the 92-kDa band was the
most prominent. These bands were considered to corre-
spond to latent MMP-9, human neutrophil lipocalin/MMP-9
complex,19 and the multiple form of MMP-9, respectively.
Based on significant Pearson’s correlation coefficientsS
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Figure 2 Serum levels of MMP-9 and MMP-2 in patients with
LAM determined by gelatin zymography. (A) Representative
zymographic profile shows relative amounts of MMP-9 (92 kDa)
and MMP-2 (72 kDa) in serum from six LAM patients and four
normal controls. L, LAM patient; C, normal control; St, stan-
dard. (B) Serum levels of MMP-9 were significantly elevated in
LAM patients compared with those in normal controls (0.7 0.1
vs. 0.1 0 AU, p< 0.0001). (C) Levels of MMP-2 did not differ
between LAM patients and normal controls (4.2 0.5 AU vs.
4.7 0.4, NS). Horizontal line indicates the mean value of each
group.
128 N. Odajima et al.between two observations (rZ 0.4, pZ 0.0452), the latter
data set is presented.
Levels of MMP-9 were significantly elevated in serum
from LAM patients compared with that from normal
controls (0.7 0.1 vs. 0.1 0 AU, p< 0.0001; Fig. 2B). On
the other hand, serum levels of MMP-2 did not differ
between LAM patients and normal controls (4.2 0.5 vs.
4.7 0.4 AU, NS; Fig. 2C). Serum MMP-9 and MMP-2 values
also did not differ between LAM patients who smoked and
those who had never smoked (0.6 0.1 vs. 0.7 0.1 AU, NS
and 3.2 0.7 vs. 4.5 0.6 AU, NS, respectively). The
statistical significance persisted in the serum levels of MMP-
9 between nonsmoking LAM patients (nZ 28) and normal
controls (0.7 0.1 vs. 0.1 0 AU, p< 0.0001). Serum MMP-
9 or MMP-2 levels also did not differ between patients with
and without angiomyolipoma (MMP-9: 0.8 0.2 vs.
0.6 0.1 AU, NS and MMP-2: 3.8 0.9 vs. 4.4 0.7 AU, NS),
between patients who received hormonal therapy and
those who did not or between those with or without TSC
(data not shown).Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.rmed.
2008.07.017.Discussion
We discovered that serum levels of MMP-9, but not of MMP-
2, were significantly higher in the patients with LAM than in
healthy controls.
MMP-9 levels in circulating blood are elevated in various
pathologic states such as asthma,21 pulmonary emphy-
sema22 and lung cancer,23 as well as in other malignancies24
and ischemic heart disease.25 Accordingly, our data imply
that LAM is one of the diseases that MMP-9 is elevated in
serum, and MMP-9 in serum is driven by circulating and/or
pulmonary LAM cells. A recent case report by Moses et al.
demonstrated that urinary MMPs comprise a potential
biomarker with which to monitor the therapeutic efficacy
of doxycycline in patients with LAM.26 Assessment of
a larger sample of patients should deepen understanding of
the involvement of MMPs in the mechanism of the disease.
In contrast to levels of serum MMP-9, those of serum
MMP-2 in patients with LAM and in normal controls did not
significantly differ. One speculation is that the constitutive
synthesis of MMP-2 by various mesenchymal cells such as
fibroblasts and endothelial cells under normal conditions
masks the increase of MMP-2 driven by LAM cells.
Various methods have been developed to quantify
circulating MMP-9 and -2, such as ELISA, gelatin zymog-
raphy, and Western blotting of either serum or plasma
samples. Several investigators have recently raised
concerns about MMP-9 analysis in the clinical environment,
such as the pre-analytical condition of the blood,20 and the
background condition of patients, since circulating MMP-9 is
reportedly elevated even in healthy smokers,27 and during
the menstrual phase in healthy women of childbearing
age.28 The present study therefore validated the feasibility
of measuring MMPs in serum. We showed that time between
blood sampling and centrifugation did not affect the level
of MMP-9 or MMP-2 in serum, and that fluctuation associ-
ated with menstrual phase did not affect serum MMP-9
levels, suggesting that this parameter (at least in normal
controls) is not affected by either the artifactual effects of
blood sampling or the dynamics of sex hormones.Furthermore, we confirmed that the levels of MMP-9 in
serum were parallel to those in plasma, regardless of
whether MMP-9 was measured by gelatin zymography or
ELISA. Overall, our data confirmed that MMP-9 can be
reliably semi-quantified in clinical serum samples by gelatin
zymography that, when prepared in a routine manner,
would simplify multi-center clinical studies.
The mechanisms responsible for the elevated serum
MMP-9 levels remain obscure, but a protein that upregu-
lates MMPs, such as extracellular matrix metalloproteinase
inducer (EMMPRIN), might be linked to the pathogenesis of
LAM, as well as fibrosing pulmonary diseases.29,30
We concluded that the levels of serum MMP-9 were
significantly elevated in patients with pulmonary LAM than
in healthy controls. Although MMP-9 is not a specific disease
marker of LAM, prospective studies could help to elucidate
the significance of serum MMP-9.
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